| http://dbpedia.org/ontology/abstract
|
Sutro Biopharma, Inc. is a public biotechn … Sutro Biopharma, Inc. is a public biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. The current CEO, William Newell, joined Sutro in January 2009. Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. To date, Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.he current standard of care is suboptimal.
, Sutro Biopharma Inc. ist ein US-amerikanis … Sutro Biopharma Inc. ist ein US-amerikanisches Biotechnologieunternehmen mit Sitz in South San Francisco, Kalifornien, das im Jahre 2003 gegründet wurde, zunächst unter dem Namen Fundamental Applied Biology. 2009 wurde der Firmenname in Sutro Biopharma geändert. Die Aktie ist an der amerikanischen Börse NASDAQ gelistet. Das Unternehmen befasst sich mit der Entwicklung von Krebs- und Autoimmuntherapeutika der nächsten Generation-Antikörperkonjugate, bispezifische Antikörper und Zytokinderivate. Ohne Einschränkung durch traditionelle Methoden der zellbasierten Entdeckung wird versucht, zielgerichtete Medikamente zu entwickeln, indem außerhalb der Einschränkungen der Zelle geforscht wird. Einschränkungen der Zelle geforscht wird.
|
| http://dbpedia.org/ontology/industry
|
http://dbpedia.org/resource/Biotechnology +
|
| http://dbpedia.org/ontology/location
|
http://dbpedia.org/resource/South_San_Francisco +
|
| http://dbpedia.org/ontology/numberOfEmployees
|
290
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Sutro_Biopharma_Inc_logo.png?width=300 +
|
| http://dbpedia.org/ontology/type
|
http://dbpedia.org/resource/Public_company +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
http://www.sutrobio.com +
|
| http://dbpedia.org/ontology/wikiPageID
|
41727124
|
| http://dbpedia.org/ontology/wikiPageLength
|
6032
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1122299624
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Immuno-oncology +
, http://dbpedia.org/resource/Category:Companies_based_in_South_San_Francisco%2C_California +
, http://dbpedia.org/resource/Antibody-drug_conjugate +
, http://dbpedia.org/resource/Cell-free_protein_synthesis +
, http://dbpedia.org/resource/Category:Companies_listed_on_the_Nasdaq +
, http://dbpedia.org/resource/Current_good_manufacturing_practice +
, http://dbpedia.org/resource/Cytokine +
, http://dbpedia.org/resource/Category:Biotechnology_companies_of_the_United_States +
, http://dbpedia.org/resource/Folate_receptor_alpha +
, http://dbpedia.org/resource/Multiple_myeloma +
, http://dbpedia.org/resource/Celgene +
, http://dbpedia.org/resource/Public_company +
, http://dbpedia.org/resource/Russell_2000_Index +
, http://dbpedia.org/resource/South_San_Francisco +
, http://dbpedia.org/resource/Category:Biopharmaceutical_companies +
, http://dbpedia.org/resource/Rational_design +
, http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_established_in_2003 +
, http://dbpedia.org/resource/Merck_&_Co. +
, http://dbpedia.org/resource/San_Carlos%2C_California +
, http://dbpedia.org/resource/Stanford_University +
, http://dbpedia.org/resource/B-cell_maturation_antigen +
, http://dbpedia.org/resource/Non-Hodgkin_lymphoma +
, http://dbpedia.org/resource/Bispecific_antibodies +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Infobox_company +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:More_citations_needed +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Companies_listed_on_the_Nasdaq +
, http://dbpedia.org/resource/Category:Companies_based_in_South_San_Francisco%2C_California +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_established_in_2003 +
, http://dbpedia.org/resource/Category:Biotechnology_companies_of_the_United_States +
, http://dbpedia.org/resource/Category:Biopharmaceutical_companies +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Company +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Sutro_Biopharma?oldid=1122299624&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Sutro_Biopharma_Inc_logo.png +
|
| http://xmlns.com/foaf/0.1/homepage
|
http://www.sutrobio.com +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Sutro_Biopharma +
|
| http://xmlns.com/foaf/0.1/name
|
Sutro Biopharma
|
| owl:sameAs |
http://yago-knowledge.org/resource/Sutro_Biopharma +
, https://global.dbpedia.org/id/gDBV +
, http://dbpedia.org/resource/Sutro_Biopharma +
, http://de.dbpedia.org/resource/Sutro_Biopharma +
, http://www.wikidata.org/entity/Q17143062 +
, http://rdf.freebase.com/ns/m.0wsdkq4 +
|
| rdf:type |
http://dbpedia.org/class/yago/YagoLegalActorGeo +
, http://dbpedia.org/class/yago/YagoLegalActor +
, http://dbpedia.org/class/yago/Company108058098 +
, http://www.wikidata.org/entity/Q24229398 +
, http://dbpedia.org/class/yago/Institution108053576 +
, http://schema.org/Organization +
, http://www.wikidata.org/entity/Q43229 +
, http://dbpedia.org/class/yago/SocialGroup107950920 +
, http://www.wikidata.org/entity/Q4830453 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#Agent +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#SocialPerson +
, http://dbpedia.org/ontology/Organisation +
, http://dbpedia.org/class/yago/DrugCompany108002578 +
, http://dbpedia.org/ontology/Company +
, http://dbpedia.org/class/yago/WikicatPharmaceuticalCompaniesOfTheUnitedStates +
, http://dbpedia.org/class/yago/YagoPermanentlyLocatedEntity +
, http://dbpedia.org/class/yago/Group100031264 +
, http://dbpedia.org/class/yago/Organization108008335 +
, http://dbpedia.org/ontology/Agent +
, http://dbpedia.org/class/yago/Abstraction100002137 +
|
| rdfs:comment |
Sutro Biopharma Inc. ist ein US-amerikanis … Sutro Biopharma Inc. ist ein US-amerikanisches Biotechnologieunternehmen mit Sitz in South San Francisco, Kalifornien, das im Jahre 2003 gegründet wurde, zunächst unter dem Namen Fundamental Applied Biology. 2009 wurde der Firmenname in Sutro Biopharma geändert. Die Aktie ist an der amerikanischen Börse NASDAQ gelistet. der amerikanischen Börse NASDAQ gelistet.
, Sutro Biopharma, Inc. is a public biotechn … Sutro Biopharma, Inc. is a public biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. The current CEO, William Newell, joined Sutro in January 2009.liam Newell, joined Sutro in January 2009.
|
| rdfs:label |
Sutro Biopharma
|
